Sanofi (NASDAQ:SNY – Get Free Report) and CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.
Volatility & Risk
Sanofi has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Sanofi and CASI Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sanofi | 0 | 12 | 8 | 1 | 2.48 |
| CASI Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Sanofi presently has a consensus target price of $53.00, indicating a potential upside of 9.89%. Given Sanofi’s stronger consensus rating and higher possible upside, analysts plainly believe Sanofi is more favorable than CASI Pharmaceuticals.
Valuation and Earnings
This table compares Sanofi and CASI Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sanofi | $49.35 billion | 2.37 | $8.84 billion | $2.02 | 23.88 |
| CASI Pharmaceuticals | $26.85 million | 0.10 | -$39.26 million | ($3.01) | -0.07 |
Sanofi has higher revenue and earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
14.0% of Sanofi shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Sanofi and CASI Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sanofi | 8.70% | 15.16% | 8.48% |
| CASI Pharmaceuticals | -183.93% | N/A | -131.54% |
Summary
Sanofi beats CASI Pharmaceuticals on 12 of the 15 factors compared between the two stocks.
About Sanofi
Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.
About CASI Pharmaceuticals
CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines, particularly for cancer and blood disorders. Its commercial and development activities have been centered largely on China. The company’s portfolio has included EVOMELA, a formulation of melphalan used in conditioning treatment for certain patients with multiple myeloma undergoing stem-cell transplantation. CASI has also pursued development and commercialization rights for additional oncology therapies, including CNCT19, an investigational CD19-directed CAR T-cell therapy.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
